Catherine A Chappell, Jennifer J Kiser, Kristina M Brooks, Riley Randolph, Ingrid S Macio, Leslie A Meyn, Sam MaWhinney, Anne-Marie Rick, Gysella B Muniz, Kyung Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Katherine E Bunge, Elizabeth E Krans, Sharon L Hillier
{"title":"索非布韦/韦帕他韦对丙型肝炎病毒携带者孕妇的药代动力学、安全性和有效性。","authors":"Catherine A Chappell, Jennifer J Kiser, Kristina M Brooks, Riley Randolph, Ingrid S Macio, Leslie A Meyn, Sam MaWhinney, Anne-Marie Rick, Gysella B Muniz, Kyung Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Katherine E Bunge, Elizabeth E Krans, Sharon L Hillier","doi":"10.1093/cid/ciae595","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Treatment of hepatitis C virus (HCV) during pregnancy can cure maternal HCV and prevent perinatal HCV transmission. The primary objective was to compare the pharmacokinetics (PK) of sofosbuvir/velpatasvir (SOF/VEL) in pregnant versus nonpregnant people.</p><p><strong>Methods: </strong>Pregnant people with chronic HCV infection were enrolled between 23-25 weeks' gestation and were provided SOF/VEL daily for 12 weeks. PK visits were performed at 3, 6 and 9 weeks. VEL, SOF and GS-331007 (the inactive metabolite of SOF) in plasma and the SOF active metabolite (007-TP) in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) were measured and compared to historical data in non-pregnant people. Maternal adverse events, delivery outcomes, the sustained virologic response 12 weeks after therapy (SVR12), infant adverse events and HCV perinatal transmission were assessed.</p><p><strong>Results: </strong>Fourteen participants were screened, and 11 enrolled. One participant discontinued treatment due to worsening of hyperemesis. VEL area under the curve (AUC) was similar to historic data in non-pregnant people, but the AUCs of SOF and GS-331007 were 38% higher and 38% lower, respectively. Concentrations of 007-TP in PBMCs were comparable or higher, whereas 007-TP in DBS were ∼50% lower in pregnancy vs. non-pregnant people. All 10 participants who completed treatment had undetectable HCV RNA at delivery. Two participants were lost to follow-up after delivery, but one had an HCV RNA through clinical care. All participants with data were cured (N=9) and none of the infants acquired HCV (N=8).</p><p><strong>Conclusions: </strong>SOF/VEL exposures were not clinically different in pregnancy and support further evaluation of antenatal SOF/VEL treatment.</p><p><strong>Funding: </strong>This study was supported by the NIH (R21HD101996), NIH/OWHR (K12HD043441), and Gilead Sciences (IN-US-342-5634).</p>","PeriodicalId":10463,"journal":{"name":"Clinical Infectious Diseases","volume":" ","pages":""},"PeriodicalIF":8.2000,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People with Hepatitis C Virus.\",\"authors\":\"Catherine A Chappell, Jennifer J Kiser, Kristina M Brooks, Riley Randolph, Ingrid S Macio, Leslie A Meyn, Sam MaWhinney, Anne-Marie Rick, Gysella B Muniz, Kyung Min Kwon, Cathleen Letterio, Sarjita Naik, Bruce Kreter, Katherine E Bunge, Elizabeth E Krans, Sharon L Hillier\",\"doi\":\"10.1093/cid/ciae595\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Treatment of hepatitis C virus (HCV) during pregnancy can cure maternal HCV and prevent perinatal HCV transmission. The primary objective was to compare the pharmacokinetics (PK) of sofosbuvir/velpatasvir (SOF/VEL) in pregnant versus nonpregnant people.</p><p><strong>Methods: </strong>Pregnant people with chronic HCV infection were enrolled between 23-25 weeks' gestation and were provided SOF/VEL daily for 12 weeks. PK visits were performed at 3, 6 and 9 weeks. VEL, SOF and GS-331007 (the inactive metabolite of SOF) in plasma and the SOF active metabolite (007-TP) in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) were measured and compared to historical data in non-pregnant people. Maternal adverse events, delivery outcomes, the sustained virologic response 12 weeks after therapy (SVR12), infant adverse events and HCV perinatal transmission were assessed.</p><p><strong>Results: </strong>Fourteen participants were screened, and 11 enrolled. One participant discontinued treatment due to worsening of hyperemesis. VEL area under the curve (AUC) was similar to historic data in non-pregnant people, but the AUCs of SOF and GS-331007 were 38% higher and 38% lower, respectively. Concentrations of 007-TP in PBMCs were comparable or higher, whereas 007-TP in DBS were ∼50% lower in pregnancy vs. non-pregnant people. All 10 participants who completed treatment had undetectable HCV RNA at delivery. Two participants were lost to follow-up after delivery, but one had an HCV RNA through clinical care. All participants with data were cured (N=9) and none of the infants acquired HCV (N=8).</p><p><strong>Conclusions: </strong>SOF/VEL exposures were not clinically different in pregnancy and support further evaluation of antenatal SOF/VEL treatment.</p><p><strong>Funding: </strong>This study was supported by the NIH (R21HD101996), NIH/OWHR (K12HD043441), and Gilead Sciences (IN-US-342-5634).</p>\",\"PeriodicalId\":10463,\"journal\":{\"name\":\"Clinical Infectious Diseases\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":8.2000,\"publicationDate\":\"2024-12-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Infectious Diseases\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/cid/ciae595\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Infectious Diseases","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/cid/ciae595","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People with Hepatitis C Virus.
Background: Treatment of hepatitis C virus (HCV) during pregnancy can cure maternal HCV and prevent perinatal HCV transmission. The primary objective was to compare the pharmacokinetics (PK) of sofosbuvir/velpatasvir (SOF/VEL) in pregnant versus nonpregnant people.
Methods: Pregnant people with chronic HCV infection were enrolled between 23-25 weeks' gestation and were provided SOF/VEL daily for 12 weeks. PK visits were performed at 3, 6 and 9 weeks. VEL, SOF and GS-331007 (the inactive metabolite of SOF) in plasma and the SOF active metabolite (007-TP) in peripheral blood mononuclear cells (PBMCs) and dried blood spots (DBS) were measured and compared to historical data in non-pregnant people. Maternal adverse events, delivery outcomes, the sustained virologic response 12 weeks after therapy (SVR12), infant adverse events and HCV perinatal transmission were assessed.
Results: Fourteen participants were screened, and 11 enrolled. One participant discontinued treatment due to worsening of hyperemesis. VEL area under the curve (AUC) was similar to historic data in non-pregnant people, but the AUCs of SOF and GS-331007 were 38% higher and 38% lower, respectively. Concentrations of 007-TP in PBMCs were comparable or higher, whereas 007-TP in DBS were ∼50% lower in pregnancy vs. non-pregnant people. All 10 participants who completed treatment had undetectable HCV RNA at delivery. Two participants were lost to follow-up after delivery, but one had an HCV RNA through clinical care. All participants with data were cured (N=9) and none of the infants acquired HCV (N=8).
Conclusions: SOF/VEL exposures were not clinically different in pregnancy and support further evaluation of antenatal SOF/VEL treatment.
Funding: This study was supported by the NIH (R21HD101996), NIH/OWHR (K12HD043441), and Gilead Sciences (IN-US-342-5634).
期刊介绍:
Clinical Infectious Diseases (CID) is dedicated to publishing original research, reviews, guidelines, and perspectives with the potential to reshape clinical practice, providing clinicians with valuable insights for patient care. CID comprehensively addresses the clinical presentation, diagnosis, treatment, and prevention of a wide spectrum of infectious diseases. The journal places a high priority on the assessment of current and innovative treatments, microbiology, immunology, and policies, ensuring relevance to patient care in its commitment to advancing the field of infectious diseases.